Correlation Engine 2.0
Clear Search sequence regions

  • adult t- cell leukemia (10)
  • AKT (2)
  • azd8055 (2)
  • human (1)
  • IL 2 (1)
  • Interleukin 2 receptor alpha (1)
  • JAK 1 (1)
  • JAK1 (3)
  • JAK2 (1)
  • mTOR (2)
  • patients (4)
  • PI3K (2)
  • ruxolitinib (2)
  • STAT (2)
  • t lymphocytes (3)
  • Sizes of these terms reflect their relevance to your search.

    Adult T-cell leukemia (ATL) is an aggressive T-cell lymphoproliferative malignancy of regulatory T lymphocytes (Tregs), caused by human T-cell lymphotropic virus 1 (HTLV-1). Interleukin 2 receptor alpha (IL-2Rα) is expressed in the leukemic cells of smoldering/chronic ATL patients, leading to constitutive activation of the JAK/STAT pathway and spontaneous proliferation. The PI3K/AKT/mTOR pathway also plays a critical role in ATL cell survival and proliferation. We previously performed a high-throughput screen that demonstrated additive/synergistic activity of Ruxolitinib, a JAK1/2 inhibitor, with AZD8055, an mTORC1/C2 inhibitor. However, effects of unintended JAK2 inhibition with Ruxolitinib limits it therapeutic potential for ATL patients, which lead us to evaluate a JAK1-specific inhibitor. Here, we demonstrated that Upadacitinib, a JAK-1 inhibitor, inhibited the proliferation of cytokine-dependent ATL cell lines and the expression of p-STAT5. Combinations of Upadacitinib with either AZD8055 or Sapanisertib, mTORC1/C2 inhibitors, showed anti-proliferative effects against cytokine-dependent ATL cell lines and synergistic effect with reducing tumor growth in NSG mice bearing IL-2 transgenic tumors. Importantly, the combination of these two agents inhibited ex vivo spontaneous proliferation of ATL cells from patients with smoldering/chronic ATL. Combined targeting of JAK/STAT and PI3K/AKT/mTOR pathways represents a promising therapeutic intervention for patients with smoldering/chronic ATL. Published by Elsevier Inc.


    Anusara Daenthanasanmak, Yuquan Lin, Meili Zhang, Bonita R Bryant, Michael N Petrus, Richard N Bamford, Craig J Thomas, Milos D Miljkovic, Kevin C Conlon, Thomas A Waldmann. Enhanced efficacy of JAK1 inhibitor with mTORC1/C2 targeting in smoldering/chronic adult T cell leukemia. Translational oncology. 2021 Jan;14(1):100913

    PMID: 33129109

    View Full Text